Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Asymptomatic Drug Resistant Staphylococcus Detected

By LabMedica International staff writers
Posted on 28 Feb 2011
Methicillin-resistant Staphylococcus aureus (MRSA) can be detected in asymptomatic patients in an emergency department (ED) setting. More...


The prevalence of asymptomatic MRSA colonization in ED patients is poorly described, particularly in the absence of skin and soft tissue infection-related complaints.

A study to assess the prevalence of nasal and extranasal staphylococcal colonization in ED patients was carried out at the Boston University School of Medicine (Boston, MA, USA). The scientists evaluated the risk factors, and characterized the strains by molecular techniques. They actively surveyed 400 patients presenting to the ED. Testing was conducted on anterior nares, oropharynx, palms, groin, perirectal area, wounds, and catheter insertion sites. Swabs taken from the various sites were cultured and any S. aureus, whether sensitive (MSSA) or resistant (MRSA) to methicillin, were characterized by a multiplex polymerase chain reaction assay.

The prevalence of colonization with MSSA was 39%, and prevalence of colonization with MRSA was 5%. Among MRSA-colonized subjects, an extranasal site tested positive in 80% of subjects, and 45% had exclusive extranasal colonization. Human immunodeficiency virus (HIV) infection showed the strongest association with MRSA colonization, with a nearly 14-fold increased risk. Among factors at least tripling the risk was a history of diabetes, presenting from a nursing home, and playing contact sports. However, among those who were colonized, 20% had no risk factors for colonization and 45% were colonized only at sites other than the nose. Of those colonized with MRSA, 55% were infected with the USA300 strain which often carries the Panton-Valentine leukocidin virulence factor and is responsible for invasive skin and soft tissue infections, necrotizing pneumonia, necrotizing fasciitis, and other serious infections in otherwise healthy hosts.

Elissa M. Schechter-Perkins, MD, M.P.H., the lead author of the study, said, "These findings suggest that current programs that screen for MRSA, which typically screen for nasal MRSA colonization among patients perceived to be at high-risk, may actually be missing a large number of patients actually colonized with MRSA. This has implications for spread of MRSA colonization and subsequent infections that nasal screening programs aim to prevent.” The study was published online on January 15, 2011, in Annals of Emergency Medicine.

Related Links:

Boston University School of Medicine



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.